Macrocyclic lactone
Approved for certain human parasite infections. Extensive preclinical cancer data; human oncology still early (trials, observation).
Read more →
This is an objectively presented site built with Grok Build 4.5
Ivermectin, fenbendazole & mebendazole — what does the research say?
An overview of studies, registries and experience worldwide — Asia, Africa, Latin America, the Middle East and integrative traditions — not only the US/EU. Summaries in English; every source linked in the original.
Preclinical
Phase I–II
Registry (NCT)
Case series
Reviews
Three substances — three tracks
All three are antiparasitic drugs under investigation for oncology drug repurposing. Evidence levels differ.
Benzimidazole (veterinary)
Used against worms in animals. Cell and animal studies show microtubule and metabolism effects. Few formal human cancer RCTs.
Read more →Benzimidazole (human)
Approved human anthelmintic. Strongest formal tracks against cancer: Michigan case, Johns Hopkins preclinical + phase I, Egypt mCRC, etc.
Read more →Protocols by cancer stage
Investigational overviews for stages I–II: what standard care involves, and how IVM/FBZ/MBZ appear in literature and registries. Not approved treatment — standard care with an oncologist always comes first.
Stages I–III
Frame for reading the protocol pages: standard care, investigational tracks, questions for the oncologist.
Open protocols →Localized disease
Early disease, high curative potential with standard care; investigational adjuncts as conversation — not replacement.
Stage I →Locally more extensive
Often multimodal adjuvant plans; formal IVM/MBZ trials more often enroll advanced disease.
Stage II →How we label evidence
| Level | Meaning | Examples on this site |
|---|---|---|
| A | Published RCT / phase II–III with outcomes | Patil 2022; Egypt mCRC MBZ |
| B | Phase I safety / prospective cohort | Gallia 2021; Hulscher 2026 |
| C | Case series / case reports | Michigan ACC; FBZ self-admin series |
| D | Cell / animal studies | Tang; Dogra; Bai (Hopkins) |
| E | Systematic or narrative review | Robalino; Chai; ReDO |
| R | Registry entry (ongoing/planned) | NCT05318469, NCT07487805, NCT01729260 |
The positive dominates the map
Cells, animals, case reports, real-world and early human studies worldwide point in the same direction. Formal “negative” cancer RCTs are few and narrow — that is why you rarely hear them.
Lab & animals
Hundreds of papers: growth inhibition, apoptosis, microtubules, glucose, immune activation, synergy with chemo/ICI.
Positive map →Humans
Michigan 19 mo; Hopkins OS 21 mo; Egypt mCRC; Hulscher cohort; ASCO PR; Tippens/case series.
USA →World
China, Korea, India, Latin America, Africa, integrative practice — not only one Western clinic.
World →Short list of the few formal limitations: see here.
Pets — parasite pressure & caregiver burden
Shared spaces + less routine deworming → more infection → sick pets → caregiver burden (owner exhaustion). Resistance is real but precise. Processes and sources under the Pets menu.
USA — positive signals
Michigan case (MBZ, 19 mo stability), Johns Hopkins phase I (median OS 21 mo), Cedars-Sinai IVM+ICI (1 PR interim), Florida ICONIC, Tippens narrative, etc.
Beyond “western medicine” only
WHO global parasite programs, Korean and Chinese research, Indian and Egyptian trials, Japanese toxicology, Latin American patient practice, Ayurveda/TCM context.
Korea · China · Japan · India
FBZ social phenomenon in Korea, IVM mechanisms from Chinese labs, Ōmura discovery, Indian phase II GBM.
Read more →Africa · Latin America · Egypt
WHO MDA, onchocerciasis, Loa loa safety, Egyptian mCRC RCT with mebendazole, patient-driven IVM use.
Read more →Ayurveda · TCM · folk protocols
IVM/FBZ/MBZ are modern molecules — but they meet traditional and integrative practice in real life.
Read more →